Ranjana H. Advani

机构：Stanford Medicine, Stanford University · ORCID：0000-0002-3219-2292

发表论文 834 篇 · 总被引 48670 次 · h-index 101

代表论文

• NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025 (2025 · Journal of the National Comprehensive Cancer Network · 被引 19)
• Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study (2025 · Blood Advances · 被引 8)
• Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up (2025 · Blood Cancer Journal · 被引 5)
• Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia (2025 · Blood Advances · 被引 5)
• An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma (2025 · NEJM Evidence · 被引 4)
• Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma (2025 · Nature Communications · 被引 3)